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ABSTRACT
The array of genome editing strategies based on
targeted double-stranded DNA break formation
have recently been enriched through the introduc-
tion of transcription activator-like type III effector
(TALE) nucleases (TALENs). To advance the testing
of TALE-based approaches, it will be crucial to
deliver these custom-designed proteins not only
into transformed cell types but also into more
relevant, chromosomally stable, primary cells. Viral
vectors are among the most effective gene transfer
vehicles. Here, we investigated the capacity of
human immunodeficiency virus type 1- and
adenovirus-based vectors to package and deliver
functional TALEN genes into various human cell
types. To this end, we attempted to assemble
particles of these two vector classes, each
encoding a monomer of a TALEN pair targeted to
a bipartite sequence within the AAVS1 ‘safe
harbor’ locus. Vector DNA analyses revealed that
adenoviral vectors transferred intact TALEN genes,
whereas lentiviral vectors failed to do so, as shown
by their heterogeneously sized proviruses in target
cells. Importantly, adenoviral vector-mediated
TALEN gene delivery resulted in site-specific
double-stranded DNA break formation at the
intended AAVS1 target site at similarly high levels
in both transformed and non-transformed cells. In
conclusion, we demonstrate that adenoviral, but
not lentiviral, vectors constitute a valuable TALEN
gene delivery platform.
INTRODUCTION
The ability to design DNA-binding motifs that recognize
pre-defined sequences of choice within complex eukaryotic
genomes is opening a wide range of basic and applied
research possibilities that involves the modulation of
endogenous gene expression and chromosomal DNA
editing. The latter aim has been mostly pursued by design-
ing zinc-finger nucleases (ZFNs) comprising a
sequence-specific array of synthetic zinc-finger motifs
fused to the nuclease domain of the type IIS restriction
endonuclease FokI (1,2). In addition, the recoding of
natural homing endonucleases for heritable genome modi-
fication purposes has also been undergoing intense
investigation (3,4). These artificial enzymes are tailored
to generate double-stranded DNA breaks (DSBs) at pre-
defined genomic sequences. As a consequence of their
activity, targeted gene knockout or chromosomal inser-
tion of exogenous DNA can ensue following the activation
and engagement of the error-prone non-homologous
end-joining (NHEJ) or the error-free homologous recom-
bination (HR) DNA repair pathways, respectively.
The recent discovery of the rules governing the recog-
nition of specific DNA sequences by bacterial transcrip-
tion activator-like type III effectors (TALEs) (5,6) has
translated in a novel and straightforward methodology
to construct proteins with customized DNA binding
specificities. TALEs are proteins found in phytopatho-
genic bacteria of the genus Xanthomonas, whose main
well-established function is to induce expression of
specific host plant genes that enhance virulence. TALEs
comprise an N-terminal translocation domain, a central
region of tandem direct repeats that confers DNA
binding specificity and a nuclear localization motif
preceding a C-terminal transcriptional activation domain
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(7). The DNA binding domain of TALEs displays a
unique architecture composed of a tandem array of typic-
ally 15.5–19.5 repeat units with circa 34 residues each (7).
Often, the only distinguishing feature among the different
repeats is a 2-amino acid hypervariable polymorphism at
positions 12 and 13 dubbed ‘repeat-variable di-residue’
(RVD). Crucially, it has been discovered that each indi-
vidual RVD dictates the binding of the repeat in which it
is embedded to a single nucleotide (5,6). Therefore, this
one repeat to one nucleotide code directly establishes a
simple rule governing TALE–DNA interactions. This
insight combined with the modular nature of the DNA
binding domain, is permitting researchers to harness
TALE-derived repeats as custom-made scaffolds on
which to assemble functional heterologous domains.
Hitherto, designer TALEs tested in vitro and in cellula
have included those with transcriptional activation or
FokI nuclease domains (8,9). The latter, called TALE nu-
cleases (TALENs) operate similarly to ZFNs in that a pair
is assembled at a given DNA sequence consisting of two
half-target sites separated by a spacer sequence (10). The
directional binding of each TALEN monomer to its re-
spective half-target site induces dimerization of the FokI
portions resulting in site-specific DNA cleavage. Impor-
tantly, in contrast to zinc-finger modules (11), there are as
of yet no indications that binding of an individual TALE
repeat to its cognate base pair is altered by neighboring
sequences. This context-independent feature combined
with the simple DNA binding code suggests that, when
compared with ZFNs, TALENs can bind a wider range
of DNA sequences and be programmed in an easier and
more predictable manner. Moreover, the ability to con-
struct functionally viable TALEN pairs with relatively
large arrays of repeats has the potential to render them
more specific than ZFNs.
Thus far, nucleic acids encoding TALENs have been
introduced into cells by nucleic acid microinjection or by
transfection methods based on chemical agents or electro-
poration (8,9,12–14). Unfortunately, these methods suffer
from low throughput or are too cytotoxic or too inefficient
in populations of non-transformed cells. Notably, the
therapeutic application and the thorough assessment of
the genome-wide TALEN specificity, for instance, will
be dependent on highly efficient TALEN delivery
systems into relevant karyotypically stable cells. In the
realm of biomedical research, this will include tissue-
specific stem and progenitor cells. From the broad
variety of methods to introduce foreign nucleic acids
into cells, viral vectors have proven to be the most effect-
ive thus far. In particular, vectors derived from the
double-stranded linear DNA human adenovirus serotype
5 and from the single-stranded positive-sense RNA lenti-
virus human immunodeficiency type 1 (HIV-1) have
become broadly used (15,16). Owing to the infection
mechanisms evolved by their parental viruses (17,18),
adenoviral and lentiviral vectors are particularly fit for
the in vitro and in vivo transduction of dividing and
non-dividing cells. In the current study, we investigated
the suitability of these two major vector classes as
delivery vehicles of TALEN sequences. We report that,
in contrast to HIV-1-based lentiviral vectors, adenoviral
vectors can package and deliver functional TALEN-
encoding expression units into transformed, immortalized
and primary human cells.
MATERIALS AND METHODS
Cells
The 293T and HeLa cells (American Type Culture
Collection) were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen). The medium used for the culturing
of the former and latter cell types was supplemented with
10 and 5% fetal bovine serum (Invitrogen), respectively.
The adenoviral vector packaging cell lines PER.C6 (19)
and PER.E2A (20) were maintained in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine
serum, 10mM MgCl2 (Sigma-Aldrich) without and with
250 mg/ml of Geneticin (Invitrogen), respectively. These
cells were kept in an atmosphere of humidified air with
10% CO2. The human myoblasts were obtained from a
Duchenne muscular dystrophy patient and were
immortalized through constitutive expression of Bmi-1
and TERT. The generation of and culture conditions for
these immortalized human myoblasts have been specified
elsewhere (21). The human bone marrow-derived primary
fetal mesenchymal stem cells (hMSCs) were cultured as
previously specified (22). The human myoblasts and
hMSCs were kept in an atmosphere of humidified air
with 5% CO2.
Recombinant DNA
A TALEN pair (Supplementary Figure S1) targeting
intron 1 of the PPP1R12C locus (AAVS1 target site:
50-TCTGTCCCCTCCACCCCAC-spacer-GACAGGAT
TGGTGACAGAA-30) were generated by Golden Gate
cloning, as previously described (9). To generate
pAdShu.TALEN-LS1.IRES.RFP and pAdShu.TALEN-
RS1.IRES.RFP, plasmids 1383.pVAX.AAVS1.TALEN.
L-94 and 1384.pVAX.AAVS1.TALEN.R-95 were digested
with Eco32I (Fermentas) and PmeI (New England
Biolabs), and the resulting 3.0-kb TALEN open reading
frame (ORF) fragments were isolated and ligated into the
Eco32I-linearized 8.8-kb plasmid vector backbone
pShuttle.IRES.DsRedEx2.1. Cells transduced with
vectors based on this construct can be traced and
quantified via the encoded red fluorescent protein (RFP)
reporter DsRedEx2.1. The first-generation (i.e. early
region 1 [E1]-deleted) fiber-modified adenoviral vector
molecular clones pAd.E1.TALEN-LS1.F50 and
pAd.E1.TALEN-RS1.F50 (Figure 2A) were assembled
by HR following transformation of Escherichia coli cells
BJ5183pAdEasy-1.50 (23) with shuttle plasmids pAdShu.
TALEN-LS1.IRES.RFP and pAdShu.TALEN-RS1.
IRES.RFP, respectively, whereas the second-generation
adenoviral vector molecular clones pAd.E1E2A.
TALEN-LS1.F50 and pAd.E1E2A.TALEN-RS1.F50
(Figure 2A) were assembled by HR following transform-
ation of E. coli cells BJ5183pAdEasy-2.50 (23) with shuttle
plasmids pAdShu.TALEN-LS1.IRES.RFP and pAdShu.
TALEN-RS1.IRES.RFP, respectively. Before transform-
ation, all shuttle plasmids were digested to completion
2 Nucleic Acids Research, 2012
 at U










with MssI. The structure and composition of lentiviral
vector constructs pLV.TALEN-LS1.i.RFP, pLV.
TALEN-RS1.i.RFP, pLV.TALEN-LS1 and pLV.
TALEN-RS1 are described in Figure 1A. The enhanced
green fluorescent protein (eGFP)-encoding plasmid
CMVPRES [(24); herein referred to as pLV.CMV.eGFP]
served as a negative control in the polymerase chain
reaction (PCR) amplifications of TALEN sequences.
Viral vectors
The production of adenoviral vectors Ad.E1.TALEN-
LS1.F50 and Ad.E1.TALEN-RS1.F50 took place in
PER.C6 cells, whereas that of adenoviral vectors
Ad.E1E2A.TALEN-LS1.F50 and Ad.E1E2A.
TALEN-RS1.F50 occurred in PER.E2A cells. The rescue
of vector particles was initiated by transfecting each of the
PacI-linearized adenoviral vector molecular clones into
their respective packaging cells by using a
polyethyleneimine-based protocol (23). The procedures
to propagate and purify the resulting viral vectors have
been described elsewhere (23). Vector titers were
determined through limiting dilutions on HeLa indicator
cells seeded at a density of 0.8 105 cells per well of
24-well plates (Greiner). At 3 days post-transduction,
frequencies of RFP-positive cells were determined
through flow cytometry by using a BD LSR II FACS
(Becton Dickinson). As a result, the titers are expressed
in terms of HeLa cell-transducing units (HTUs) per milli-
liter. The HIV-1-based and vesicular stomatitis virus
glycoprotein-G (VSV-G)-pseudotyped lentiviral vectors
were generated by transfecting 293T cells essentially as
specified elsewhere (25) except for the use of 7.5 106
cells in T75-cm2 flasks instead of 1.75 107 cells in
T175-cm2 flasks. A total amount of 12.85 mg of DNA
was transfected corresponding to 2:1:1 mixtures of
bi-cistronic lentiviral vector transfer plasmid, packaging
construct psPAX2 (Addgene plasmid 12260) or
psPAX2D116N (25) and VSV-G pseudotyping construct
pLP/VSVG (Invitrogen). The psPAX2- and
psPAX2D116N-based production systems yielded second-
generation integration competent and integrase-defective
lentiviral vectors (IDLVs), respectively. The mono-
cistronic lentiviral vectors with an integration-competent
and integrase-defective phenotype were made instead with
a third-generation packaging system based on the
pMDLg/pRRE (Addgene plasmid 12251) and pMDLg/
pRRED64V packaging plasmids, respectively. Vector
titers were determined by using HIV-1 p24gag
immunocapture (Perkin Elmer).
Immunofluorescence microscopy
Fifty thousand HeLa cells were seeded in wells of 24-well
plates and, after an overnight incubation period, they were
either mock-transduced or were transduced with Ad.E1.
TALEN-LS1.F50 or with Ad.E1.TALEN-RS1.F50 at 3
HTU/cell. Three days post-transduction, the cells were
subjected to immunostaining essentially as described else-
where (26) except for the use of an influenza hemagglu-
tinin (HA)-specific mouse monoclonal IgG1 antibody
(HA.11 clone 16B12; Covance) together with a goat
anti-mouse IgG (H+L) Alexa 488-conjugated secondary
antibody (A-11001; Molecular Probes).
Western blot analysis
HeLa cells seeded at a density of 1 105 cells per well of
24-well plates (Greiner) were transduced with different
amounts of Ad.E1.TALEN-LS1.F50 or Ad.E1.
TALEN-RS1.F50. At 72 h post-transduction, the cell
monolayers were rinsed with ice-cold phosphate buffered
saline (pH 7.4) and lysed in 100 ml of ice-cold RIPA buffer
composed of 50mM Tris-HCl (pH 7.5), 150mM NaCl,
0.1% sodium dodecyl sulphate (SDS), 0.5% sodium
deoxycholate and 1% Nonidet P-40 plus a cocktail of
protease inhibitors (Complete Mini, Roche Applied
Science). Next, the cell lysates were spun at 4C for
8min at 16 400 g. The proteins were subjected to electro-
phoresis through an SDS 7.5% polyacrylamide gel after
which they were transferred onto an Immobilon-P
membrane (Millipore) by electroblotting overnight. After
incubation with Tris-buffered saline and tween (TBST)
blocking solution consisting of 10mM Tris-HCl (pH
8.0), 150mM NaCl and 0.2% Tween-20 supplemented
with 10% non-fat dry milk powder (Elk, Campina), the
membranes were incubated overnight at 4C with the
HA-specific monoclonal antibody F-7 (SC-7392, Santa
Cruz Biotechnology) diluted 1:1000. Subsequently, the
membranes were washed once with TBST at room tem-
perature and subjected to a 3-h incubation period with a
horseradish peroxidase-conjugated goat anti-mouse sec-
ondary antibody (SC-2005; Santa Cruz Biotechnology)
diluted 1:5000 in blocking solution. Finally, the mem-
branes were rinsed and processed for protein detection
by chemiluminescence as described elsewhere (27).
The western blot analysis to detect TALEN expression
following lentiviral vector transduction was performed as
follows. Hundred-thousand HeLa cells were seeded in
wells of 6-well plates and were transduced with 200 ng of
p24gag of LV.TALEN-LS1 or 400 ng of p24gag of
IDLV.TALEN-LS1 in the presence of polybrene (8 mg/
ml). Forty-eight hours after transduction, the cells were
harvested, and total protein lysates were prepared as
aforementioned. Fifty micrograms of protein were sub-
jected to electrophoresis through a NuPAGE 4–12%
Bis-Tris Gel (Invitrogen) and were transferred onto a
nitrocellulose membrane (Hybond-ECL, Amersham)
that was subsequently exposed overnight at 4C to a
mouse monoclonal antibody against the HA-tag (clone
12CA5 a gift from Valeria Marigo). A horseradish
peroxidase-conjugated goat anti-mouse secondary
antibody (Amersham) was diluted 1:2000 in blocking
solution. The proteins were detected by using a chemilu-
minescence labelling detection reagent (ECL; GE
Healthcare Life Sciences). For protein loading normaliza-
tion, the same membrane was stripped and incubated with
a 2000-fold diluted mouse monoclonal antibody directed
against b-actin (sc-81178, Santa Cruz Biotechnology).
Isolation and structural analysis of adenoviral vector DNA
DNA was isolated from purified adenoviral vector par-
ticles as follows. To a 50-ml vector preparation aliquot it
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Figure 1. Structural analyses of HIV-1-based lentiviral vectors harboring TALEN sequences in transduced cells. (A) Genetic organization of
lentiviral vector constructs. Diagram of bicistronic pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP and of monocistronic pLV.TALEN-LS1
and pLV.TALEN-RS1 lentiviral vector transfer plasmids. The bicistronic constructs code for the AAVS1-specific custom-made nucleases TALEN-LS1
or TALEN-RS1 and, through an IRES sequence, an RFP reporter, whereas the monocistronic plasmids encode exclusively the AAVS1-specific
designer nucleases. Each of the TALEN proteins are tagged by an HA antigen located close to their N-termini (not drawn). Gray boxes with broken
arrow, hybrid 50 LTR containing CMV and HIV-1 sequences; gray boxes without broken arrow, self-inactivating (SIN) 30 LTR; , HIV-1 packaging
signal; RRE, Rev-responsive element; cPPT, central polypurine tract; WPRE, Woodchuck hepatitis virus posttranscriptional regulatory element. In
pLV.TALEN-LS1.i.RFP and pLV.TALEN-RS1.i.RFP, the ORFs are under the transcriptional control of the CMV promoter and the
polyadenylation signal present within the SIN 30 LTR, whereas the ORFs in pLV.TALEN-LS1 and pLV.TALEN-RS1 are under the control of
the CMV promoter and the bovine growth hormone polyadenylation signal (bGH). Primers, PCR products and Southern blot probe used are depicted
as half-arrows, black bars and gray bar, respectively, and are drawn in relation to their respective vector DNA sequences. For the sake of simplicity,
plasmid backbone sequences are not shown. The sizes of the PCR products expected from the amplification of full-length lentiviral vector genomes
are indicated. The 6.4-kb AflII restriction fragment corresponding to intact DNA from LV.TALEN-LS1 or LV.TALEN-RS1 is also indicated.
(B) PCR analyses of TALEN-encoding HIV-1-based lentiviral vector genomes following transduction of HeLa cells. PCR amplifications with the
aid of the primers shown in Figure 1A were carried out using, as template, total cellular DNA from mock-transduced HeLa cells, plasmid
pAd.E1.TALEN-LS1.F50, plasmid pLV.CMV.eGFP or nuclease-free H20 (lanes 1, 2, 3 and 4, respectively). PCR amplifications using the same
primer pairs were performed in parallel on DNA extracted from HeLa cells transduced with integration-competent LV.TALEN-RS1 (lane 5),
integrase-defective IDLV.TALEN-RS1 (lane 6), Ad.E1.TALEN-RS1.F50 (lane 10) or integration-competent LV.TALEN-RS1.i.RFP (lane 11).
Extra PCR controls supplementing those corresponding to lanes 1 through 4 were provided by using DNA isolated from HeLa cells exposed to
an LV.TALEN-RS1 preparation made in parallel but deploying pUC19 instead of lentiviral vector packaging construct psPAX2 (lane 7) or incubated
with pLV.TALEN-RS1 mixed or not mixed with the DNA transfection agent ExGen500 (lanes 8 and 9, respectively). Lanes M, Gene Ruler DNA
Ladder Mix. A primer pair targeting the human HPRT1 served to control the integrity of the cellular DNA. (C) Clonal analysis. Southern blot
analysis of AflII-digested genomic DNA from HeLa cell clones 1 through 15 stably transduced with LV.TALEN-LS1. The vector-specific probe
that was used is shown in Figure 1A (horizontal gray bar). Lane M, 1 kb molecular-weight marker. The parental transfer plasmid pLV.TALEN-LS1
treated with AflII served as an internal control for intact vector DNA. (D) PCR screening of genomic DNA from HeLa cell clones stably transduced
with LV.TALEN-LS1. Upper and lower panel, PCR products resulting from the use of the primer pairs CMV-prom.F/TALE.as.Pr2 and
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was added 12 ml of DNaseI buffer [130 mM Tris-HCl (pH
7.5), 1.2mM CaCl2 and 50mM MgCl2], 8 ml of DNaseI
(10mg/ml; Fermentas) and 50 ml of Milli-Q water
(Millipore). This mixture was incubated for 30min at
37C, after which, the DNaseI was inactivated for 1 h at
55C after the addition of 2.4 ml of 0.5M ethylenediami-
netetraacetic acid (EDTA) (pH 8.0), 6 ml of 10% SDS and
1.5 ml of a Proteinase K (21.4mg/ml; Fermentas). Next,
the vector DNA was purified by using the QIAEX II
Gel Extraction Kit (Qiagen) and was eluted in 30 ml of
10mM Tris-HCL (pH 7.8). After measuring its concentra-
tion with the aid of a Nanodrop (Thermo Scientific), the
recovered DNA was subjected to BcuI (Fermentas) diges-
tion and agarose gel electrophoreses (200 ng) and to PCR
analyses (1 ng). The PCR amplifications were carried out
with primers TALEN-Seq-F (50-CCAGCTGCTGAAGA
TCGCCAAGC-30) and TALEN-Seq-R (50-CTATCCTG
AGTGGAATTTCTGGC-30) whose target sequences
flank the TALEN DNA-binding motifs. The DNA
samples were subjected to PCR with 0.4mM of these
primers (Eurofins MWG Operon), 0.1mM of each
dNTP (New England Biolabs), 1 Colorless GoTaq
Flexi buffer, 1mM MgCl2 and 2.5 units of GoTaq DNA
polymerase (all from Promega). The PCR cycles were per-
formed in a DNA Engine Tetrad 2 Peltier Thermal Cycler
(Bio-Rad) using the following cycling parameters. After a
3-min denaturation step at 95C, the samples were sub-
jected to 30 cycles consisting of 30 s at 95C, 30 s at 60C
and 4min at 72C. The reactions were terminated by a
final elongation period of 3min at 72C. One-fifth of
these reactions were subjected to electrophoresis through
1% agarose gels in 1 Tris-acetate-EDTA (TAE) buffer.
Moreover, to establish the integrity of TALEN sequences
in adenoviral vector particles at the nucleotide level, the
2.4-kb BcuI fragments from Ad.E1.TALEN-LS1.F50 or
from Ad.E1.TALEN-RS1.F50 DNA were inserted into a
XbaI-linearized pUC19 backbone and were sequenced by
using M13-F (50-GACGTTGTAAAACGACGGCCAGT
-30) and M13-R (50-CAGGAAACAGCTATGACC
ATGA-30) primers.
Surveyor nuclease S mutation detection assay
Genomic DNA was extracted from mock-transduced or
adenoviral vector-transduced target cells as described
before (28). Briefly, at 72 h post-infection, the cells were
collected by trypsinization and incubated overnight at
55C in 500ml of lysis buffer [100 mM Tris-HCl (pH
8.5), 5mM EDTA, 0.2% SDS, 200mM NaCl] supple-
mented with freshly added Proteinase K at a final concen-
tration of 100 ng/ml. Next, the cell lysates were extracted
twice with a buffer-saturated phenol:chloroform:isoamyl
alcohol mixture (25:24:1) and once with chloroform. The
DNA in the aqueous phase was precipitated by the
addition of 2.5 volumes of absolute ethanol and 0.5
volumes of 7.5M ammonium acetate (pH 5.5). After
washing with 70% ethanol, the DNA pellet was mildly
dried and dissolved in 100 ml of Tris-EDTA buffer
(10mM Tris-HCl [pH 8.0] and 1mM EDTA) supple-
mented with RNase A (Fermentas) at a final concentra-
tion of 100mg/ml.
The recovered DNA was used for PCR analyses. The
extent of AAVS1 processing by the error-prone NHEJ
DNA repair pathway was evaluated by using the
Surveyor assay (SURVEYOR Mutation Detection Kit,
Transgenomics) according to the manufacturer’s instruc-
tions. In brief, genomic DNA purified from
mock-transduced or adenoviral vector-transduced cells
was used as a template to PCR amplify a 469-bp
AAVS1 sequence flanking the TALEN pair target site.
PCR mixtures contained 0.4 mM of primers AAVS1-
CEL1-F (50-TTCGGGTCACCTCTCACTCC-30) and
AAVS1-CEL1-R (50-GGCTCCATCGTAAGCAAA
CC-30), 0.1mM of each dNTP, 1 Colorless GoTaq
Flexi buffer, 1mM MgCl2 and 2.5 units of GoTaq DNA
polymerase. The PCR cycles were performed using the
following cycling conditions. An initial denaturation step
at 95C for 5min was followed by 40 cycles of 30 s at
95C, 30 s at 61C and 30 s at 72C. The reactions were
terminated by a final elongation period of 5min at 72C.
The PCR products, after being heat denaturated and
re-annealed according to the manufacturer’s specifica-
tions, were treated with the nucleotide mismatch-sensitive
Surveyor nuclease S (SNS) enzyme to detect small inser-
tions and deletions (indels) caused by NHEJ-dependent
DNA repair. Samples were loaded on a 1.7% agarose
gel, and electrophoresis was performed in 1 TAE
buffer. The DNA was visualized by in-gel staining with
2 mg/ml of ethidium bromide (Sigma-Aldrich) in 1 TAE
buffer followed by stain removal in Milli-Q water. The
frequencies of target DNA cleavage were determined by
using the ImageJ software (National Institutes of Health,
USA). Genomic DNA derived from hMSC cells
co-transduced with a 1:1 mixture of Ad.E1.TALEN-
LS1.F50 and Ad.E1.TALEN-RS1.F50 at a total multipli-
city of infection (MOI) of 24 HTU/cell, served as template
Figure 1. Continued
TAL-N.s/TAL-N.as, respectively, on HeLa cell clones 1 through 8 (note: clone 8 turned out to yield two closely sized and vector-specific amplicons,
thus the nomenclature 8.1 and 8.2). PCR amplifications on plasmid pLV.TALEN-LS1 served as a positive control (+), whereas those on nuclease-free
water (W) and HeLa genomic DNA (H) provided for negative controls. Lanes M, Gene Ruler DNA Ladder Mix. (E) Structural analyses of proviral
vector DNA. DNA sequencing of amplicons retrieved from HeLa cell clones 2, 5, 6, 7 and 8 after PCR amplifications with primers CMV-prom.F
and TALE.as.Pr2 (Figure 1D, upper panel). Upper panel, summary of the TALE repeat arrays present in the indicated LV.TALEN-LS1-transduced
HeLa cell clones. The respective predicted target sites, lengths, size reduction in relation to the wild-type sequence and the number of 102-bp long
TALE repeat units found to be deleted, are also indicated. Lower panel, alignment of the TALEN-LS1 DNA sequences retained in the various
proviruses (horizontal thin lines) drawn in relation to the reference wild-type sequence (horizontal thick line). (F) TALEN protein detection. HA
tag-directed western blot analysis of full-length TALEN-LS1 expression in 293T producer cells (lane 1), IDLV.TALEN-LS1- and LV.TALEN-LS1-
transduced HeLa cells (lane 2 and lane 4, respectively) and in pLV.TALEN-LS1-transfected 293T cells used to generate these IDLV.TALEN-LS1 and
LV.TALEN-LS1 vector preparations (lanes 3 and 5, respectively). Lane 6, HeLa cells transfected with pLV.TALEN-LS1. The b-actin served as
loading control.
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to PCR amplify the AAVS1 target site region. The
pGEM-T Easy TA cloning vector (Promega) was ligated
to the resulting 469-bp amplicons and was transformed
into E. coli strain DH5a. Plasmid DNA from 20
randomly selected colonies was extracted, and the respect-
ive inserts were subjected to DNA sequencing by using the
M13-F primer.
PCR analyses of TALEN sequences following lentiviral
vector-mediated gene transfer
Total cellular DNA from HeLa cells incubated with
integration-competent or IDLVs was isolated as specified
elsewhere (28). The recovered DNA was subjected to three
different PCR protocols. To determine the integrity of the
cellular DNA, a PCR targeting the human housekeeping
gene hypoxanthine phosphoribosyltransferase 1 (HPRT1)
was performed. To this end, reactions containing 0.4mM
of primers hHPRT.1 and hHPRT.2 (29), 0.1mM of each
dNTP, 1 Colorless GoTaq Flexi buffer, 1mM MgCl2
and 2.5 units of GoTaq DNA polymerase were assembled.
The PCR cycles were performed using the following
cycling conditions. An initial denaturating step at 95C
for 5min was followed by 30 cycles of 30 s at 95C, 30 s
at 60C and 120 s at 72C.
Figure 2. Structural analysis of TALEN-encoding adenoviral vector
genomes. (A) DNA structures of the first-generation adenoviral
vectors Ad.E1.TALEN-LS1.F50 and Ad.E1.TALEN-RS1.F50 and
of the second-generation adenoviral vectors Ad.E1E2A.TALEN-
LS1.F50 and Ad.E1E2A.TALEN-RS1.F50 drawn in relation to
those of their respective plasmid clones. The adenoviral vector and
shuttle plasmid DNA templates are depicted as BcuI physical maps
with numerals specifying the different restriction fragment sizes in kilo-
bases (kb). These DNA molecules harbor a bi-cistronic expression unit
coding for the AAVS1-specific artificial nucleases TALEN-LS1 or
TALEN-RS1 and, through an IRES sequence, an RFP reporter. The
ORFs are under the transcriptional control of the cytomegalovirus
Figure 2. Continued
immediate-early gene promoter (CMV) and the simian virus 40 (SV40)
polyadenylation signal. The central regions of TALEN-LS1 and
TALEN-RS1 encode a tandem of 17.5 TALE repeats that define speci-
ficity to the AAVS1 target sequence at the human chromosome 19
(19q13.42-qter). C-terminally both TALENs contain the non-specific
cleavage domain of FokI, whose catalytic activity is contingent on
DNA binding-dependent dimerization. Each of the TALEN proteins
are tagged by an HA antigen located close to their N-termini (not
drawn). The thick and thin lines represent adenoviral vector and
plasmid backbone sequences, respectively. , human adenovirus
serotype 5 packaging signal; Ad L-ITR and Ad R-ITR, ‘left’ and
‘right’, respectively, adenoviral inverted terminal repeat. F50, ORF
encoding chimeric fiber composed of basal shaft domains from adeno-
virus serotype 5 fused to apical shaft and knob motifs from adenovirus
serotype 50. The kanamycin-resistance gene (KanR) and the prokaryotic
origin of replication (ori) are also indicated. (B) Restriction fragment
length analysis of Ad.E1.TALEN-LS1.F50 and Ad.E1.TALEN-
RS1.F50 genomes treated with BcuI. Plasmids pAd.E1.TALEN-
LS1.F50 and pAd.E1.TALEN-RS1.F50 served as a reference. The
sizes (in kb) of the DNA restriction fragments resulting from the
BcuI treatment are indicated on the left. The arrowhead points to the
2.4-kb DNA fragments diagnostic for intact, non-rearranged, TALE-
derived DNA sequences within TALEN-encoding genes. Marker,
molecular-weight marker Gene Ruler DNA Ladder Mix. (C) PCR
analysis on DNA isolated from Ad.E1.TALEN-LS1.F50 and
Ad.E1.TALEN-RS1.F50 particles using primers TALEN-Seq-F and
TALEN-Seq-R (F and R half arrows, respectively). These primers,
drawn in relation to their respective target sequences, amplify most
of the TALEN-LS1 and TALEN-RS1 DNA including the 17 102-bp
tandem DNA repeats. The position (arrowheads) and size (in kb) of
the 2.1-kb amplicon diagnostic for intact TALEN transgenes are
indicated at the right. Marker, Gene Ruler DNA Ladder Mix. H20,
PCR performed with nuclease-free water instead of vector DNA
template. (D) Autoradiogram of MunI-treated extrachromosomal
DNA isolated from HeLa cells transduced with Ad.E1.TALEN-
LS1.F50 or with Ad.E1.TALEN-RS1.F50 at MOIs of 10, 5 and 1
HTU/cell. The DNA, extracted at 3 days post-transduction, was sub-
jected to Southern blot analysis using a 397-bp probe hybridizing to a
sequence encoding the NH2 terminus of the TALEN-L
S1 and
TALEN-RS1 proteins.
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A second set of PCR mixtures were assembled to
amplify a 458-bp TALEN sequence corresponding to the
N-terminal, non-repetitive region, of each nuclease. These
consisted of 0.4mM of primers TAL-N.s (50-CCTTACGA
CGTGCCTGACTACG-30) and TAL-N.as (50-CGCTTG
GCGATCTTCAGC-30), 0.1mM of each dNTP, 1
Colorless GoTaq Flexi buffer, 1mM MgCl2 and 2.5
units of GoTaq DNA polymerase. The PCR cycles were
performed using the following cycling conditions. An
initial denaturating step at 95C for 5min was followed
by 30 cycles of 30 s at 95C, 30 s at 62C and 30 s at 72C.
Finally, the third PCR set was designed to amplify a
2.5-kb TALEN sequence encompassing the region
encoding the repetitive DNA-binding domain of each
nuclease. To this end, reactions containing 0.4mM of
primers CMV-prom.F (50-AATGGGCGGTAGGCGTG
TA-30) and TALE.as.Pr2 (50-GTCGGGTCTGCTCAGC
TG-30), 0.1mM of each dNTP, 1 Colorless GoTaq
Flexi buffer, 1mM MgCl2 and 2.5 units of GoTaq DNA
polymerase were assembled. The PCR cycling parameters
consisted of an initial denaturating step at 95C for 5min
followed by 40 cycles of 30 s at 95C, 30 s at 60C and
180 s at 72C. In all three protocols, the PCR amplifica-
tions were terminated by a final elongation period of 5min
at 72C. Control samples subjected to the same PCR
conditions were carried out in parallel. These controls
consisted of using, in place of DNA from lentiviral
vector-transduced HeLa cells, DNA from mock-
transduced HeLa cells, DNA from Ad.E1.TALEN-
RS1.F50-transduced HeLa cells, pAd.E1.TALEN-
LS1.F50, pLV.CMV.eGFP or MilliQ water. Additional
controls were provided by PCR amplifications on DNA
isolated from HeLa cells exposed to an LV.TALEN-RS1
preparation made with the aid of pUC19 instead of the
lentiviral vector packaging construct psPAX2 (Addgene
plasmid 12260) or on DNA extracted from cells trans-
fected with pLV.TALEN-RS1 transfer plasmid mixed or
not mixed with ExGen500 (Fermentas).
DNA sequencing of proviral vector DNA in
LV.TALEN-LS1-transduced HeLa cell clones was per-
formed as follows. The PCR conditions and cycling par-
ameters specified earlier in the text were applied on
chromosomal DNA isolated from HeLa cell clones 2, 5,
6, 7 and 8. Next, the resulting PCR products were inserted
into the pGEM-T Easy TA cloning vector (Promega) and
were transformed into GT115 E. coli cells (InvivoGen).
Finally, the vector inserts were subjected to DNA
sequencing by using the oligodeoxyribonucleotides
M13-F, M13-R and TALEN-Seq-F.
Southern blot analysis
Total cellular DNA from 4 105 hMSCs exposed to
three different MOIs of Ad.E1.TALEN-LS1.F50 or of
Ad.E1.TALEN-RS1.F50 was extracted 72 h post-
transduction and purified as described before (28). After
overnight digestion with BamHI (Fermentas), 10 mg of
DNA per sample was resolved in a 1% agarose gel in
1 TAE buffer. Next, the DNA was transferred by capil-
lary action onto an Amersham Hybond-XL membrane
(GE Healthcare Life Sciences) using a standard
Southern blot technique. A 397-bp probe specific for
TALEN DNA corresponding to the N-terminal region
of the nucleases was isolated by digestion of
1383.pVAX.AAVS1.TALEN.L-94 with XbaI and PstI
(both from Fermentas) and was purified with the aid of
the QIAEX II gel extraction kit (Qiagen). This DNA
probe was radiolabelled with EasyTide (a-32P) dCTP
(3000Ci/mmol; Perkin Elmer) by using the DecaLabel
DNA labelling system (Fermentas). Before its addition
onto the membrane, the radiolabelled fragment was
separated from unincorporated dNTPs through
size-exclusion chromatography with the aid of
Sephadex-50 columns (GE Healthcare Life Sciences). A
Storm 820 PhosphorImager (Amersham) as used for the
detection of the probe-hybridizing DNA. Finally, images
were acquired and processed by using the Storm scanner
control 5.03 and the ImageQuant Tools 3.0 software, re-
spectively (both from Amersham).
HeLa cell clones were derived from an LV.TALEN-LS1-
transduced population by limiting dilution using a seeding
density of 0.3 cells per well in 96-well plates. Southern blot
analysis of genomic DNA extracted from various HeLa
cell clones was performed as follows. Genomic DNA was
extracted from 5 106 cells from each clone using a
QIAamp DNA Mini Kit according to the manufacturer’s
instructions (Qiagen). Ten micrograms of genomic DNA
was digested overnight with AflII (New England Biolabs),
subjected to electrophoresis through a 0.8% agarose gel
and was transferred onto a Hybond-XL nylon membrane.
Before DNA detection, this membrane was incubated with
a (a-32P)-labelled 814-bp probe corresponding to the
lentiviral vector long-terminal repeat (LTR) elements R
and U5, the packaging signal and part of the
Rev-responsive element.
RESULTS
HIV-1-based lentiviral vectors introduce rearranged
TALEN genes into human cells
We started by investigating the feasibility of generating
HIV-1-based lentiviral vectors to deliver
TALEN-encoding expression units into human cells.
Although the long-term presence of artificial nucleases in
cells is, clearly, undesirable in most experimental settings,
lentiviral vectors can be made with in-built stringent
drug-controllable transgene expression systems (30) or
class I integrase mutant moieties (31,32). These integrase
mutations are non-pleiotropic, as they confer an
integration-defective phenotype to the vectors by specific-
ally disabling the chromosomal insertion step of their
DNA. IDLVs are, therefore, being increasingly exploited
to deliver transgenes whose expression is only required
during a short timeframe in populations of cycling cells.
Examples include IDLV-mediated delivery of
transposases, homing endonucleases and ZFNs (33–36).
Therefore, we constructed the transfer plasmids pLV.
TALEN-LS1 and pLV.TALEN-RS1 to package the
lentiviral vector pairs LV.TALEN-LS1/IDLV.TALEN-
LS1 and LV.TALEN-RS1/IDLV.TALEN-RS1, respect-
ively. These constructs encode a TALEN enzyme
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(i.e. TALEN-LS1 or TALEN-RS1) specific for the AAVS1
locus at the human chromosome 19 (19q13.42-qter).
Moreover, we also constructed pLV.TALEN-LS1.i.RFP
and pLV.TALEN-RS1.i.RFP to make lentiviral vector
particles carrying bicistronic cassettes encoding
TALEN-LS1 and TALEN-RS1, respectively, and through
an IRES, the RFP reporter.
To investigate the integrity of vector genomes in target
cells, we carried out transduction experiments on HeLa
cells deploying the HIV-1-based lentiviral vector set har-
boring the TALEN-RS1 ORF. Following DNA extraction
from vector-transduced cells, we set up a PCR assay
(Figure 1A) based on the use of primer pairs framing
the repeats of the TALEN ORF and its upstream region
encoding the nuclease’s N-terminus (CMV-prom.F/
TALE.as.Pr2) or targeting exclusively the latter segment
(TAL-N.s/TAL-N.as). PCR amplifications with primers
CMV-prom.F and TALE.as.Pr2 on DNA extracted
from HeLa cells transduced with LV.TALEN-RS1,
IDLV.TALEN-RS1 or LV.TALEN-RS1.i.RFP did not
yield detectable levels of 2.5-kb amplicons diagnostic for
full-length TALEN-RS1 sequences (Figure 1B, upper
panels, lanes 5, 6 and 11, respectively). In fact, in these
samples, the only PCR products that could be discerned
were those consistent with heterogeneously sized
sub-genomic templates whose molecular-weight range
spanned from about 0.8 to 1.5 kb. Significantly, PCR
amplifications carried out on the same DNA templates
with primers TAL-N.s and TAL-N.as, gave rise to prop-
erly sized 0.46-kb PCR products indicating that the
non-repetitive upstream portion of the TALEN-RS1
ORF did not suffer major rearrangements in transduced
cells (Figure 1B, middle panels). Of note, equivalent
results were obtained in complementary transduction ex-
periments that made use of the HIV-1-based lentiviral
vector set carrying the TALEN-LS1 ORF (not shown).
To validate these data, PCR amplifications were done in
parallel on control samples. These negative and positive
controls consisted of water (Figure 1B, lane 4) or DNA
extracted from mock-transduced HeLa cells (Figure 1B,
lane 1), Ad.E1.TALEN-RS1.F50-transduced HeLa cells
(Figure 1B, lane 10), plasmid pAd.E1.TALEN-LS1.F50
(Figure 1B, lane 2) or plasmid pLV.CMV.eGFP
(Figure 1B, lane 3). Additional controls consisted of
PCR amplifications on DNA isolated from HeLa cells
exposed to an LV.TALEN-RS1 preparation made with
pUC19 instead of the lentiviral vector packaging construct
psPAX2 (Figure 1B, lane 7) or incubated with plasmid
pLV.TALEN-RS1 mixed or not mixed with the DNA
transfection agent ExGen500 (Figure 1B, lanes 8 and 9,
respectively). PCR amplifications targeting HPRT1 served
as a control for DNA template integrity (Figure 1B, lower
panels).
To complement these PCR results on whole target cell
populations, we carried out Southern blot analysis on
genomic DNA from individual HeLa cell clones derived
from a bulk population transduced with LV.TALEN-LS1.
To this end, the chromosomal DNA from 15 clones was
digested with AflII, Southern blotted and incubated with
the probe depicted in Figure 1A. To serve as a
molecular-weight reference, the parental transfer plasmid
pLV.TALEN-LS1 was subjected to the same procedures.
Results depicted in Figure 1C demonstrate that none of
the tested clones yielded the AflII 6.4-kb fragment diag-
nostic for full-length LV.TALEN-LS1 proviruses. The
PCR screening of chromosomal DNA from HeLa cell
clones 1 through 8 with primers pairs CMV-prom.F/
TALE.as.Pr2 and TAL-N.s/TAL-N.as (Figure 1A) estab-
lished that the proviral LV.TALEN-LS1 deletions located
specifically within the TALE repeat region (Figure 1D).
To obtain a more detailed knowledge about these re-
arrangements, we cloned and sequenced the 2.5-kb
amplicons obtained after PCR on genomic DNA from
HeLa cell clones 2, 5, 6, 7 and 8 (Figure 1D, upper
panel). Interestingly, this data revealed that the various
clones comprised TALE unit-length deletions leading,
as a result, their sizes to differ by multiples of 102 bp
(Figure 1E, upper panel). In these clones, the number of
deleted RVD-containing repeat units (RVD units)
varied between a minimum of 5 (clone 7) and a
maximum of 15 (clone 5). Moreover, the alignment of
the retrieved DNA sequences with that of the original
wild-type DNA shows the involvement of the majority
of the 17.5 TALE repeats in the vector rearrangements
(Figure 1E, lower panel and Supplementary Figure S2).
Thus, these data provide no evidence for any particular
‘hotspot’ within the TALE array at which template recom-
bination events preferentially take place.
Finally, we investigated through HA tag-directed
western blot analysis, TALEN-LS1 expression following
addition of 400 ng of p24gag of LV.TALEN-LS1 or
IDLV.TALEN-LS1 onto HeLa cultures. Consistent with
the vector DNA analyses, these experiments failed to yield
detectable HA-specific signals at a molecular-weight
expected from full-length TALEN-LS1 proteins in
protein lysates corresponding to vector-transduced cells.
In contrast, these HA-specific signals could be readily
detected in control lysates derived from pLV.TALEN-
LS1-transfected HeLa cells or 293T producer cells
(Figure 1F). To serve as controls for assembly of
LV.TALEN-LS1 or IDLV.TALEN-LS1 particles, we
produced in parallel LV and IDLV vector preparations
carrying a human PGK1 promoter-driven eGFP reporter
(LV.PGK.eGFP and IDLV.PGK.eGFP, respectively).
Exposure of HeLa cell cultures to 400 ng of p24gag of
LV.PGK.eGFP or IDLV.PGK.eGFP led to the transduc-
tion of 98% and 91% of the target cells, respectively (not
shown).
Taken together, these data indicate that TALEN se-
quences introduced into human cells through
HIV-1-based lentiviral vectors are prone to extensive re-
arrangements resulting presumably from deletions
involving the TALE repeats.
Adenoviral vectors deliver full-length TALEN genes into
human cells inducing high-level DSB formation at an
endogenous chromosomal target locus
In light of the previous results, we sought to investigate
the feasibility of using adenoviral vectors as an alternative
delivery platform for the introduction of intact TALEN
genes into human cells. To this end, the full-length
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adenoviral vector molecular clones pAd.E1.TALEN-
LS1.F50 and pAd.E1.TALEN-RS1.F50 were assembled
through HR in E. coli to produce the E1-deleted adeno-
viral vectors Ad.E1.TALEN-LS1.F50 and Ad.E1.
TALEN-RS1.F50, respectively (Figure 2A). These clones
contain, in place of E1 from the prototypic adenovirus
serotype 5, a bicistronic expression unit encoding a
monomer of the AAVS1-specific TALEN pair and, for
tracing and quantification purposes, the RFP reporter
(Figure 2A). In addition, their adenoviral genomic se-
quences harbor an ORF coding for a vector retargeting
chimeric fiber composed of serotype 5 basal shaft domains
fused to apical shaft and knob domains derived from the
species B adenovirus serotype 50 (F50). The latter
CD46-interacting motif allows for entry of vectors dis-
playing species B fiber domains into human cells lacking
on their surface the Coxsackie B virus and adenovirus
receptor, CAR. Of note, among these cells, there are
various therapeutically relevant tissue-specific normal
and malignant stem and progenitor cell types (37–41). In
addition, plasmids pAd.E1E2A.TALEN-LS1.F50 and
pAd.E1E2A.TALEN-RS1.F50 were also constructed
to assemble fiber-modified E1- plus E2A-deleted particles
Ad.E1E2A.TALEN-LS1.F50 and Ad.E1E2A.
TALEN-RS1.F50, respectively (Figure 2A). By virtue of
their lack of E2A, these so-called second-generation
adenoviral vectors have been shown to display a
much-reduced de novo replication and ‘leaky’ viral gene
expression profile in target cells when compared with
their E1-deleted, first-generation, counterparts [see, for
instance, (20)].
We started by testing whether TALEN sequences are
stably maintained in first- and second-generation adeno-
viral vectors following their rescue and subsequent propa-
gation on their respective packaging cell lines. Thus, these
producer cells were transfected with PacI-treated plasmids
pAd.E1.TALEN-LS1.F50, pAd.E1.TALEN-RS1.F50,
pAd.E1E2A.TALEN-LS1.F50 or pAd.E1E2A.
TALEN-RS1.F50 to assemble the corresponding adeno-
viral vector particles (Figure 2A). The rescued particles
were subsequently amplified following serial propagation
on increasing amounts of packaging cells. The frequency
of RFP-positive producer cells, as monitored by direct
fluorescence microscopy, revealed a clear propagation
round-dependent increase in vector yields (not shown).
The Ad.E1.TALEN-LS1.F50 and Ad.E1.TALEN-
RS1.F50 vectors, corresponding to two independent
batches, were purified through CsCl buoyant density
gradient ultracentrifugation, after which, the integrity of
their genomes was probed by BcuI restriction fragment
length analysis. To serve as an additional molecular-
weight reference, the parental plasmids pAd.E1.
TALEN-LS1.F50 and pAd.E1.TALEN-RS1.F50 were
taken along in this analysis. Results depicted in
Figure 2B show that the overall DNA restriction pattern
is consistent with that expected from linear full-length
adenoviral vector genomes (Figure 2A). Thus, import-
antly, the internal TALE-encompassing restriction frag-
ments derived from Ad.E1.TALEN-LS1.F50 and
Ad.E1.TALEN-RS1.F50 DNA did co-migrate with
those corresponding to their respective 2.4-kb parental
plasmid counterparts (Figure 2B, arrowheads). Results
equivalent to these were obtained following the structural
analyses of DNA isolated from Ad.E1E2A.TALEN-
LS1.F50 and Ad.E1E2A.TALEN-RS1.F50 (Supplemen-
tary Figure S3). Next, we performed a more sensitive
PCR-based assay using primers bracketing the 17.5
repeats of TALEN-LS1 and TALEN-RS1 to search for
rearranged TALEN sequences in the purified vector prep-
arations. Again, parental constructs pAd.E1.TALEN-
LS1.F50 and pAd.E1.TALEN-RS1.F50 served as control
DNA templates. This assay led to the detection of 2.1-kb
amplicons whose size is diagnostic for vector DNA
genomes harboring intact TALEN-encoding genes
(Figure 2C). Moreover, Southern blot analysis of extra-
chromosomal DNA isolated from hMSCs exposed to dif-
ferent amounts of Ad.E1.TALEN-LS1.F50 or Ad.E1.
TALEN-RS1.F50 also led to the sole detection of
full-length TALEN sequences in the transduced cells
(Figure 2D). Finally, we cloned into pUC19 the 2.4-kb
DNA species from BcuI-treated Ad.E1.TALEN-
LS1.F50 or BcuI-treated Ad.E1.TALEN-RS1.F50 and
sequenced the inserts from six individual clones. DNA
sequence information corresponding to the 7 most down-
stream and to the 3–4 most upstream TALEN repeats
could be retrieved (Supplementary Figure S4). The nucleo-
tide sequences analysed revealed to be isogenic to that in
the parental constructs with no evidence for point muta-
tions, local rearrangements and/or deletions.
Transduction experiments deploying Ad.E1.TALEN-
LS1.F50 and Ad.E1.TALEN-RS1.F50 alone or mixed
together were carried out on CAR-positive human cervix
carcinoma HeLa cells (42) and on two CAR-negative cell
types, namely, immortalized myoblasts from a Duchenne
muscular dystrophy (DMD) patient and hMSCs (42,43).
The use of relatively modest MOIs was sufficient to trans-
duce most target cells in the various cultures (Figure 3A).
Importantly, HA tag-specific immunofluorescence micros-
copy and western blot analyses (Figure 3B and 3C, re-
spectively) demonstrated the expression of TALEN-LS1
and TALEN-RS1 genes in target HeLa cells following
their transduction with Ad.E1.TALEN-LS1.F50 and
Ad.E1.TALEN-RS1.F50, respectively. Taken together,
we conclude that first-generation adenoviral vectors can
deliver expression units encoding full-length TALENs into
human cells.
Finally, to investigate the functionality of TALENs
introduced into human cells through adenoviral vector-
mediated gene transfer, we deployed the Surveyor
mutation detection assay (Figure 4A). PCR amplification
of AAVS1 target DNA from mock-transduced cells or
from cells transduced with Ad.E1.TALEN-LS1.F50 or
with Ad.E1.TALEN-RS1.F50 yielded amplicons that,
on denaturation and reannealing, were not susceptible to
site-specific cleavage by the mismatch-sensitive SNS
enzyme (Figure 4B, solid arrowhead in the upper panel).
These data validated the read-out system by
demonstrating the absence of indels at the AAVS1 locus
under these experimental control conditions. However,
co-transduction of HeLa cells and DMD myoblasts with
Ad.E1.TALEN-LS1.F50 and Ad.E1.TALEN-RS1.F50
resulted in efficient cleavage of the endogenous
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chromosomal target sequence, as evidenced by the de-
tection of large amounts of SNS-digested products
(Figure 4B, open arrowheads in the lower panels). This
conclusion was substantiated through vector dose-
response experiments on HeLa cells, human myoblasts
and hMSCs (Figure 4C). Additional transduction experi-
ments on hMSCs that made use of the second-generation
adenoviral vectors Ad.E1E2A.TALEN-LS1.F50 and
Ad.E1E2A.TALEN-RS1.F50 produced results similar
to those shown in Figure 4C (Supplementary Figure S5).
Finally, we sought to confirm the involvement of the
NHEJ pathway in the repair of the TALEN-induced
DSBs. To this end, we cloned the AAVS1-specific PCR
products resulting from genomic DNA of hMSCs
exposed to Ad.E1.TALEN-LS1.F50 and Ad.E1.
TALEN-RS1.F50 at an MOI of 12 HTU/cell each. DNA
sequencing of 20 randomly selected clones revealed that 12
of these harbored indels characteristic of NHEJ-mediated
repair of DSBs (Figure 4D).
We conclude that delivery of TALENs by first- and
second-generation adenoviral vectors is a highly effective
approach to generate in a cell type-independent manner
site-specific DSBs at an endogenous human target locus.
DISCUSSION
The approaches aiming at editing or modulating the ex-
pression of specific endogenous genes and targeting
chromosomal insertion of exogenous DNA have recently
been enriched with the introduction of sequence-specific
designer TALEs. To broaden the use of TALE-based
proteins and to most optimally screen and evaluate their
performance in many settings, it will be crucial to expand
the range of cellular delivery tools for these molecules.
Despite their promise and favorable set of attributes
when compared with other custom-made sequence-specific
proteins, TALEs are relatively large proteins whose DNA
binding specificity is governed by an extensive tract of re-
petitive sequences. Of note, DNA repeats are known to be
particularly unstable motifs. Indeed, examples of both
physiological and function-impairing processes associated
with instability of tandem repeats are copious and cover
virtually all biological systems from viruses and prokary-
otes to eukaryotes (44–46). Also in the context of gene
delivery vehicles, such as those based on adenoviral and
lentiviral vectors, examples exist pointing to certain repeti-
tive sequence arrangements as the culprits behind DNA
instability (47–50). Bearing this in mind, in the present
study, we sought to investigate the suitability of adeno-
viral and HIV-1-based lentiviral vectors, two of the most
commonly used viral vector systems, to serve as TALEN
gene delivery platforms.
We report that HIV-1-based lentiviral vector genomes
bearing TALEN sequences are prone to rearrangements in
target cells. In this regard, the structural analyses of these
genomes in HeLa cell populations and in individual HeLa
cell clones by PCR, Southern blot and DNA sequencing
indicate that most of the rearrangements occurred through
recombination events involving the TALE repeat array,
ultimately leading to deletions with various sizes. The
Figure 3. Adenoviral vector-mediated delivery of TALEN genes into
transformed and non-transformed human cells. (A) Gene transfer
efficiency. Upper panel, phase-contrast and live-cell RFP direct fluor-
escence microscopy on HeLa cells transduced with Ad.E1.
TALEN-LS1.F50 or with Ad.E1.TALEN-RS1.F50 at an MOI of 6
HTU/cell or with a mixture of the two adenoviral vectors at an MOI
of 6 HTU/cell each. Lower panel, RFP direct fluorescence microscopy
on immortalized DMD myoblasts and on primary hMSCs transduced
with Ad.E1.TALEN-LS1.F50 or with Ad.E1.TALEN-RS1.F50 at an
MOI of 12 HTU/cell or co-transduced with a 1:1 mixture of Ad.E1.
TALEN-LS1.F50 and Ad.E1.TALEN-RS1.F50 at a total MOI of 24
HTU/cell. The fluorescence microscopy images were acquired at 48 h
post-infection. (B) HA tag-specific immunofluorescence microscopy on
HeLa cells mock-transduced or transduced with Ad.E1.
TALEN-LS1.F50 or with Ad.E1.TALEN-RS1.F50 at an MOI of 3
HTU/cell. The direct fluorescence microscopy and the immunofluores-
cence microscopy were carried out at 48 and 72 h post-infection, re-
spectively. (C) HA tag-directed western blot analysis of protein lysates
derived from HeLa cell cultures incubated for 72 h with
Ad.E1.TALEN-LS1.F50 or with Ad.E1.TALEN-RS1.F50. The
MOIs deployed are indicated.
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Figure 4. Targeted disruption of the chromosomal AAVS1 locus. (A) Schematic representation of the Surveyor mutation detection assay used to
probe TALEN activity in human cells. Assembly of the TALEN pair at the bipartite target sequence results in local DSB formation. The error-prone
NHEJ DNA repair pathway links the broken chromosomal ends introducing in the process small insertions and deletions (indels) at the junction
(gray boxes). PCR on chromosomal DNA with primers framing the target site yields a mixture of amplicons representing the heterogeneous
population of mutated sequences and non-modified alleles. Denaturation and re-annealing of this mixture results in DNA species with internal
base pairs that are mismatched. The SNS enzyme, by preferentially recognizing and cleaving at DNA sequences with such mismatched base pairs,
yields low-molecular-weight DNA fragments (open arrowheads) that can be resolved from undigested DNA (solid arrowheads) through conventional
agarose gel electrophoreses. Parallel samples not treated with SNS () served as a negative control. (B) TALEN activity at AAVS1. Upper panel,
Surveyor assay on chromosomal DNA isolated from HeLa cells not exposed (mock) or exposed to Ad.E1.TALEN-LS1.F50 or to
Ad.E1.TALEN-RS1.F50 at a high and a low dose (i.e. 6 and 2 HTU/cell, respectively). Lower panels, Surveyor assay on chromosomal DNA
extracted from HeLa cells and DMD myoblasts (left and right panels, respectively). HeLa cells were mock-transduced () or were co-transduced with
6 HTU/cell of Ad.E1.TALEN-LS1.F50 and 6 HTU/cell of Ad.E1.TALEN-RS1.F50 (+). Human myoblasts were mock-transduced () or were
co-transduced with 12 HTU/cell of Ad.E1.TALEN-LS1.F50 and 12 HTU/cell of Ad.E1.TALEN-RS1.F50 (+). Solid and open arrowheads indicate
the positions of undigested and SNS-digested DNA molecules, respectively. White numerals correspond to the percentage of target site cleavage.
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DNA sequence analyses in particular revealed that these
rearrangements of the TALE array, albeit variable in
number, consisted of precise as opposed to randomly
truncated deletions of individual TALE repeats.
Conversely, we found that TALEN sequences are stably
maintained in first- and second-generation adenoviral
vectors following their serial propagation in producer
cells. Indeed, the TALEN transgenes in the adenoviral
vector genomes presented neither large rearrangements
nor small-scale mutations as revealed by restriction
fragment length analysis and DNA sequencing, respect-
ively. Importantly, transduction experiments with the
TALEN-encoding adenoviral vectors led to DSB forma-
tion at the intended target chromosomal locus in trans-
formed and non-transformed human cells at similarly high
frequencies.
Clearly, viruses from the Adenoviridae and Retroviridae
families display diametrically different structural features,
life cycles and replication strategies (15,51,52). The latter
aspect in particular is likely to contribute to the disparate
stability of TALEN ORFs in adenoviral versus
HIV-1-based lentiviral vectors. Adenoviruses replicate
via a DNA strand-displacement mechanism using a
virus-encoded high-fidelity DNA polymerase and a
single-stranded DNA-binding protein that, by coopera-
tively coating the displaced single-stranded replicative
intermediates, presumably inhibits spurious intramolecu-
lar hybridization (52,53). Retroviruses, on the other hand,
encode error-prone reverse transcriptases (RTs), which
convert their double-copy RNA genomes into linear
double-stranded DNA templates that serve as substrates
for proviral chromosomal insertion (51). The RTs of
simple and complex retroviruses also display a RNase H
activity responsible for the digestion of the RNA compo-
nent of hybrid RNA:DNA duplex intermediates.
Moreover, they share a low template affinity and
processivity. These features seem to have evolved to
allow RT to undergo at least two obligate template
switching events (i.e. minus-strand and plus-strand DNA
transfer) to complete full-length viral DNA synthesis and,
as ‘byproduct’, generate genotypic diversity through re-
combination. It is known, however, that the presence of
direct repeats in retroviral genomes increases the likeli-
hood for additional inter- and intra-molecular template
switching events, often resulting in the deletion of one of
the repeats plus intervening sequences (47,48,54,55). In
fact, the insertion of direct repeats in retroviral genomes
provides for an elegant model system to study the RT
template switching process in vivo or to induce precise re-
arrangements of cis- and trans-acting elements in retro-
viral vectors (54,56). Of note, the frequency of template
switching increases with the size of and the distance
between the direct repeat units. The latter finding
suggests that spacing favors template ‘looping’, which, in
turn, aids in the intra-strand alignment of direct repeats,
RT template switching and ensuing intra-molecular dele-
tions (55). The models for these direct repeat-induced de-
letions (48,54,55) postulate that during reverse
transcription, RT and the nascent DNA strand dissociates
from the RNA template owing to the aforementioned
RNaseH activity and intrinsic low template affinity.
Segments and, eventually, all nascent DNA strand hybrid-
izes to the RNA template at the distal ‘acceptor’ repeat
serving as a novel ‘ectopic’ initiation point for
RNA-dependent DNA synthesis. The net result of these
processes is often homogenously sized deletions of the
retroviral genome. In contrast to simple direct repeat
pairs, TALE sequences present a tract of numerous and
contiguous repeats. Thus, each of these arrayed repeat
units provide for multiple potential positions at which
RT template switching may occur. This corollary is con-
sistent with the heterogeneous and subgenomic-sized
population of TALEN-containing HIV-1-based lentiviral
vector proviruses that were detected in stably transduced
clones, as it is with the proviral vector DNA sequences
found in their cells. In fact, by showing precise as opposed
to truncated deletions of TALE repeats, the DNA
sequencing data do indicate the involvement of a mechan-
ism based on hybridization of similar sequences, which
underlies RT template switching. This is strengthen by
the observation that, of the six independent molecular
clones analysed, four contain sequence ‘footprints’ con-
sistent with the occurrence of more than one RT
template switch event (Figure 1E, clones 2, 5, 8.1 and
8.2). These data have implications for the delivery of
TALE-containing transgenes through lentiviral vectors in
that proteins with specificities for unintended and multiple
chromosomal DNA positions can be assembled, poten-
tially leading to deleterious effects in transduced cells.
Therefore, cells exposed to TALE protein derivatives
that operate as monomers, such as artificial transcrip-
tional activators or repressors, might be particularly
vulnerable. Finally, in this regard, HA-directed immuno-
fluorescence microscopy on HeLa cells transduced with
TALEN-encoding HIV-1-based lentiviral vector particles
did reveal the presence of HA tag-positive cells. These
data suggest that despite their variable number of
deleted repeats, TALE-containing transgenes transferred
by HIV-1-based lentiviral vectors can yield enough
protein to be detected through this assay (not shown).
Notwithstanding these findings, one can envision
strategies that might minimize or overcome the instability
Figure 4. Continued
(C) Dose-response of TALEN activity. Surveyor assay on cellular DNA from HeLa cells, DMD myoblasts and hMSCs untreated or treated with
different doses of 1:1 mixtures of Ad.E1.TALEN-LS1.F50 and Ad.E1.TALEN-RS1.F50. In these dose-response co-transduction experiments, the
total amounts of vector applied on HeLa cells were 12, 4, 1.3, 0.4 and 0.15 HTU/cell, whereas on DMD myoblasts and hMSCs, HTU/cell were 24, 8,
2.7, 1.0 and 0.3. Solid and open arrowheads indicate the positions of undigested and SNS-digested DNA molecules, respectively. White numerals
correspond to the percentage of target site cleavage. (D) Sequence analysis. DNA sequencing of cloned AAVS1-specific amplicons resulting from
PCR amplifications on genomic DNA isolated from hMSCs co-transduced with Ad.E1.TALEN-LS1.F50 and Ad.E1.TALEN-RS1.F50 at 12 HTU/
cell each. The presence of indels in 12 of 20 clones, ‘footprint’ for NHEJ processing of DSBs, demonstrates at the nucleotide level the
TALEN-mediated cleavage of the chromosomal AAVS1 target site.
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of TALEN sequences in these vectors. For instance, by
exploiting the degeneracy of the genetic code, the individ-
ual TALE motifs within the array could be re-engineered
by the introduction of judiciously chosen silent substitu-
tions to increase sequence divergence among repeats.
Regarding this issue, it has been shown via a lentiviral
vector direct repeat deletion assay that deletion
frequencies can decrease steeply with incremental repeat
sequence divergence (57). Finally, it is worth pointing out
that future experiments will be required to establish
whether the assembly of rearranged TALE repeats follow-
ing HIV-1-based lentiviral vector transductions also takes
place while deploying other classes of retroviral vector
systems.
In conclusion, TALEN sequences are prone to re-
arrangements following their introduction into human
cells by HIV-1-based lentiviral vectors. As a result,
vector-mediated TALEN gene transfer using these gene
carriers will be dependent on new optimization strategies.
Conversely, we demonstrate that first- and second-
generation adenoviral vectors are amenable to the
transfer of full-length TALEN genes into human cells.
Importantly, the resulting TALEN protein yields suffice
to induce high-level DSB formation at an endogenous
chromosomal target locus.
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42. Gonçalves,M.A.F.V., Holkers,M., Cudré-Mauroux,C., van
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